BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22561362)

  • 1. Comparative assessment of transient exposure of paclitaxel or zotarolimus on in vitro vascular cell death, proliferation, migration, and proinflammatory biomarker expression.
    Steinfeld DS; Liu AP; Hsu SH; Chan YF; Stankus JJ; Pacetti SD; Tai JT
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):179-86. PubMed ID: 22561362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells.
    Clever YP; Cremers B; Krauss B; Böhm M; Speck U; Laufs U; Scheller B
    EuroIntervention; 2011 May; 7 Suppl K():K32-42. PubMed ID: 22027725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
    Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A
    Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan.
    Segev A; Nili N; Osherov AB; Qiang B; Wong AJ; Pillarisetti S; Strauss BH
    EuroIntervention; 2010 May; 6(1):134-40. PubMed ID: 20542809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries.
    Parry TJ; Brosius R; Thyagarajan R; Carter D; Argentieri D; Falotico R; Siekierka J
    Eur J Pharmacol; 2005 Nov; 524(1-3):19-29. PubMed ID: 16271360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells.
    Matter CM; Rozenberg I; Jaschko A; Greutert H; Kurz DJ; Wnendt S; Kuttler B; Joch H; Grünenfelder J; Zünd G; Tanner FC; Lüscher TF
    J Cardiovasc Pharmacol; 2006 Dec; 48(6):286-92. PubMed ID: 17204907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid inhibits proliferation of human coronary vascular cells (SI/MPL-ratio: 0.5): a novel candidate for systemic and local therapy of postinterventional restenosis.
    Voisard R; Krebs R; Baur R; Hombach V
    Coron Artery Dis; 2010 Aug; 21(5):286-91. PubMed ID: 20508518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
    Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
    FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model.
    Salu KJ; Bosmans JM; Huang Y; Hendriks M; Verhoeven M; Levels A; Cooper S; De Scheerder IK; Vrints CJ; Bult H
    Cardiovasc Res; 2006 Feb; 69(2):536-44. PubMed ID: 16386237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression.
    Chen YW; Smith ML; Sheets M; Ballaron S; Trevillyan JM; Burke SE; Rosenberg T; Henry C; Wagner R; Bauch J; Marsh K; Fey TA; Hsieh G; Gauvin D; Mollison KW; Carter GW; Djuric SW
    J Cardiovasc Pharmacol; 2007 Apr; 49(4):228-35. PubMed ID: 17438408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of intrinsic apoptotic pathway by Re-188 irradiation and paclitaxel in coronary artery smooth muscle cells.
    Friesen C; Lubatschofski A; Glatting G; Debatin KM; Reske SN
    Q J Nucl Med Mol Imaging; 2008 Sep; 52(3):289-95. PubMed ID: 17380098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antirestenotic mechanisms of everolimus on human coronary artery smooth muscle cells: inhibition of human coronary artery smooth muscle cell proliferation, but not migration.
    Lavigne MC; Grimsby JL; Eppihimer MJ
    J Cardiovasc Pharmacol; 2012 Feb; 59(2):165-74. PubMed ID: 21983747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the effects of vitamin C, sirolimus, and paclitaxel on the growth of endothelial and smooth muscle cells for cardiovascular medical device applications.
    Kakade S; Mani G
    Drug Des Devel Ther; 2013; 7():529-44. PubMed ID: 23836963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progesterone induces human leukocyte antigen-g expression in vascular endothelial and smooth muscle cells.
    Sheshgiri R; Rao V; Tumiati LC; Xiao R; Prodger JL; Badiwala M; Librach C; Delgado DH
    Circulation; 2008 Sep; 118(14 Suppl):S58-64. PubMed ID: 18824770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARγ attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells.
    Zhang LL; Gao CY; Fang CQ; Wang YJ; Gao D; Yao GE; Xiang J; Wang JZ; Li JC
    Cardiovasc Res; 2011 Dec; 92(3):484-93. PubMed ID: 21880694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental assessment of effects of antiproliferative drugs of drug-eluting stents on endothelial cells.
    Miura K; Nakaya H; Kobayashi Y
    Cardiovasc Revasc Med; 2015 Sep; 16(6):344-7. PubMed ID: 26253188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform.
    Jaschke B; Michaelis C; Milz S; Vogeser M; Mund T; Hengst L; Kastrati A; Schömig A; Wessely R
    Cardiovasc Res; 2005 Dec; 68(3):483-92. PubMed ID: 16111664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early activation of internal medial smooth muscle cells in the rabbit aorta after mechanical injury: relationship with intimal thickening and pharmacological applications.
    Louis H; Lacolley P; Kakou A; Cattan V; Daret D; Safar M; Bonnet J; Daniel Lamazière JM
    Clin Exp Pharmacol Physiol; 2006; 33(1-2):131-8. PubMed ID: 16445712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents.
    Muldowney JA; Stringham JR; Levy SE; Gleaves LA; Eren M; Piana RN; Vaughan DE
    Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):400-6. PubMed ID: 17158352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.